Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Relapsed and Refractory Lymphoma
NCT00082888Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoint: Proportion of Participants With Confirmed Response. Started Mar 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00082888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082888.